OB:PHOPharmaceuticals
Photocure (OB:PHO) Stock Faces Margin Squeeze Despite Revenue Growth
Photocure came into this print with a stock that has slipped over the past week and quarter, even as its long term uro oncology pitch has been about steady profitable growth. Q2 cut across that story. The company reported revenue of NOK 142.5m with a small net loss after a very strong profit in Q1, as higher operating costs and business development spending squeezed margins.
For a market already cautious after a 19% decline over 90 days, this mix of solid top line progress and pressure on...